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Abstract:  
Synaptic neurodegeneration is thought to be an early event initiated by 
soluble β-amyloid (Aβ) aggregates that closely correlates with cognitive decline 
in Alzheimer disease (AD). Apolipoprotein ε4 (APOE4) is the most common 
genetic risk factor for both familial AD (FAD) and sporadic AD; it accelerates Aβ 
aggregation and selectively impairs glutamate receptor function and synaptic 
plasticity. However, its molecular mechanisms remain elusive and these synaptic 
deficits are difficult to monitor. AD- and APOE4-dependent plasma biomarkers 
have been proposed, but synapse-related plasma biomarkers are lacking. We 
evaluated neuronal pentraxin 1 (NP1), a potential CNS-derived plasma 
biomarker of excitatory synaptic pathology. NP1 is preferentially expressed in 
brain and involved in glutamate receptor internalization. NP1 is secreted 
presynaptically induced by Aβ oligomers, and implicated in excitatory synaptic 
and mitochondrial deficits. Levels of NP1 and its fragments were increased in a 
correlated fashion in both brain and plasma of 7-8 month-old E4FAD mice 
relative to E3FAD mice. NP1 was also found in exosome preparations and 
reduced by dietary DHA supplementation. Plasma NP1 was higher in E4FAD+ 
(APOE4+/+/FAD+/-) relative to E4FAD- (non-carrier; APOE4+/+/FAD-/-) mice, 
suggesting NP1 is modulated by Aβ expression. Finally, relative to normal 
elderly, plasma NP1 was also elevated in patients with mild cognitive impairment 
(MCI) and elevated further in the subset who progressed to early-stage AD 
dementia.  In those patients, there was a trend towards increased NP1 levels in 
APOE4 carriers relative to non-carriers. These findings indicate that NP1 may 
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represent a potential synapse-derived plasma biomarker relevant to early 
alterations in excitatory synapses in MCI and early-stage AD. 
Keywords: Alzheimer disease, β-amyloid, plasma biomarkers, neuronal pentraxin 
1, APOE, MCI, dementia, EFAD mice 
 
Highlights  
 Neuronal pentraxin 1 (NP1) is a potential plasma biomarker of synaptic 
dysfunction. 
 NP1 is increased in both brain and plasma in mouse models of AD.  
 In transgenic AD mice, brain and plasma NP1 levels correlated closely. 
 Both brain and plasma NP1 levels were reduced by DHA 
supplementation.   
 NP1 is increased in patients with MCI and mild AD dementia. 
 
Introduction  
        Synaptic degeneration is one of the earliest pathological hallmarks of 
Alzheimer disease (AD).  Synapse loss, not Aβ burden, is the major correlate of  
cognitive impairment and disease progression (Terry et al., 1991). Thus 
therapeutic strategies for AD should include synapse-protective interventions 
(Shankar et al., 2007) but synaptic degeneration cannot be directly monitored. 
Overwhelming evidence supports the idea that soluble oligomeric Aβ (oAβ) 
represents the major Aβ toxic species that contributes to early synaptic and 
cognitive deficits in AD (Ma et al., 2006, Shankar et al., 2007, Gong and Iqbal, 
2008, Tomic et al., 2009, Danysz and Parsons, 2012, Ma et al., 2013), involving
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(Guntupalli et al., 2016) and NMDA 
receptor-induced excitotoxicity (Snyder et al., 2005, Shankar et al., 2007, Li et 
al., 2011).  
The APOE4 allele is the most common genetic risk factor for AD. It 
increases AD risk by 4-15 fold and is present in more than half of all patients with 
MCI or dementia due to AD (Bu, 2009, Hua et al., 2011). Human APOE4 
accelerates amyloid deposition, reduces amyloid clearance and glucose uptake, 
and stabilizes oAβ. Since clinical symptoms of AD only emerge after apparently 
irreversible neurological degeneration, early interventions in high-risk APOE4 
carriers may require early diagnostic and surrogate biomarkers. ApoE4 increases 
t Aβ (Hashimoto et al., 2012) and 
oAβ within the interstitial fluid (Hudry et al., 2013), co-localizes with oAβ, and 
enhances synaptic oAβ localization (Koffie et al., 2012). However, we lack Aβ- 
and/or apoE4-regulated synapse-derived blood biomarkers for clinical studies.  
ApoE4 also appears to modulate cerebral metabolism independently of its 
effects on Aβ deposition (Jagust et al., 2012), as regional reductions in 
fluorodeoxyglucose-positron emission tomography (FDG-PET) signaling can be 
seen in younger APOE4 carriers several decades prior to Aβ deposition and the 
possible onset of dementia (Reiman et al., 2004). This may be a direct 
consequence of apoE4-mediated synaptic deficits, which include downregulation 
of synaptic mitochondrial proteins (Shi et al., 2014) and dendritic spines 
(Dumanis et al., 2009). The selective effects of apoE4 (versus apoE3) on 
mitochondria and excitatory synapses could be related to APOER2/reelin 
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receptor control of AMPA and NMDA receptor surface activity (Chen et al 2010). 
Neuronal pentraxin 1 (NP1) and its receptor (NPR) are primarily 
expressed in excitatory neurons, where NPR is involved in the function of AMPA 
receptors at the synapse (Schlimgen et al., 1995, Cho et al., 2008) including 
GluA1 (Lee et al 2017). NP1 negatively regulates mitochondrial function, 
transport and caspase activation through 
 (Clayton et al., 2012) and negatively regulates excitatory synapse 
density (Figueiro-Silva et al., 2015). Since the expression of neuronal pentraxins 
is disrupted in AD brain and AD animal models (Abad et al., 2006, Bilousova et 
al., 2015, Cummings et al., 2017, Neuner et al., 2017), we investigated whether 
NP1 might serve as excitatory synapse derived plasma biomarker that is related 
to Aβ and/or apoE isoform effects. 
 
Materials and methods  
Reagents and antibodies. All chemical reagents were purchased from 
Sigma-Aldrich, unless otherwise stated. Immunohistochemical and biochemical 
analyses utilized mouse monoclonal antibodies to Alix (Cell Signaling 
Technology Cat# 2171S, RRID:AB_2299455), Aβ (6E10, Covance Research 
Products Inc Cat# SIG-39320-200, RRID:AB_662798), drebrin (MBL 
International Cat# D029-3, RRID:AB_591275), PSD-95 (UC Davis/NIH 
NeuroMab Facility Cat# 75-028, RRID:AB_2307331), rabbit polyclonal antibodies 
to NP1 (Abgent Cat# AP7272c, RRID:AB_2236168) and Aβ (DAE, home-made 
(Lim et al., 2001)). Thromboplastin D was obtained from ThermoFisher 
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(Middletown, VA). Recombinant NP1 was obtained from GenScript (Piscataway, 
NJ).  
Experimental animals. All animal procedures were approved by the 
Institutional Animal Care Use Committee of the Greater Los Angeles VA 
Healthcare System. EFAD transgenic (Tg) mice expressing 5 familial AD (FAD) 
mutations (Oakley et al., 2006) with human (h) APOE3 (E3FAD) or hAPOE4 
(E4FAD), specifically 5xFAD+/-/APOE+/+, were used for this study, as well as 
EFAD- (non-carrier; APOE4+/+/FAD-/-) mice (Oakley et al., 2006). The EFAD mice 
were developed by Dr. Mary Jo LaDu (Department of Anatomy and Cell Biology, 
University of Illinois at Chicago). 
The effects of Aβ on brain NP1 levels were also examined in wild-type 
(WT) B6129SF2 mice. At 4 months of age, these mice were implanted with 
intracerebroventricular (icv) pumps containing a solution of Aβ42 oligomers 
(released at 50 ng/hour) and human HDL (37 μg/h, Calbiochem, CA; for Aβ 
oligomer stabilization) or HDL alone as previously described (Frautschy et al., 
2001, Begum et al., 2008). All animals were infused for 2 weeks. 
Laboratory mice were maintained on two basic diets. A standard breeder 
chow base diet (Mouse Diet PMI 5015, LabDiet) containing 11% fat and 0.18% 
omega-3 fatty acid as alpha linolenic acid was fed to EFAD, EFAD-, and WT 
mice that were used to characterize NP1 levels in brain, plasma, and plasma 
exosomes. Prior work suggests that excitatory synaptic marker loss and caspase 
activation are sensitive to dietary docosahexaenoic acid (DHA) supplementation 
(Calon et al., 2004, Calon et al., 2005). Therefore, separate cohorts of EFAD 
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mice were assigned custom diets from 3 to 7 months of age: a DHA-depleting 
base diet containing 5% fat with high n-6 linoleic acid with or without DHA 
supplementation (Calon et al., 2004). These mice were divided into 4 treatment 
groups; E3FAD and E4FAD mice were fed the high n-6 polyunsaturated fatty 
acid (PUFA) diet either with or without 0.6 % DHA (D; DHASCO oil, Martek, 
Columbia, MD). 
 Tissue preparation. At the conclusion of all experiments, mice were 
anesthetized with a lethal dose of pentobarbital (100 mg/kg) and perfused with a 
phosphate buffer with protease and phosphatase inhibitors as previously 
described (Calon et al., 2005). Brains were removed and one hemisphere was 
post-fixed in a formalin solution, sectioned by cryostat, and then used for 
immunohistochemical analyses. The other hemisphere was dissected and the 
hippocampal region was snap frozen in liquid nitrogen for subsequent 
biochemical analyses. 
Exosome preparation. We used ultracentrifugation methods to prepare 
plasma exosome fractions. Plasma exosomes were isolated per published 
protocol. Briefly, plasma was diluted 1:5 with PBS containing protease and 
phosphatase inhibitors [PhosSTOP and cOmplete (Roche Diagnostics, 
Indianapois IN)], and then sequentially spun at 300 x g for 10 minutes at 4°C, 
2000 x g for 10 minutes at 4°C, and 10,000 x g for 30 minutes at 4°C to remove 
cells and debris. The resulting supernatant was then centrifuged at 100,000 x g 
for 2 hours at 4°C. The exosome pellet was subsequently resuspended in PBS 
with protease/phosphatase inhibitors prior to being snap frozen.  
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Western blotting. Mouse hippocampal tissue was extracted into two 
fractions. Samples were initially sonicated in Tris-buffered saline (TBS) then 
centrifuged at 100,000 x g for 20 minutes at 4°C. The resulting supernatant 
represents the soluble-cytosol (TBS) fraction. The remaining pellets were then 
sonicated in immunoprecipitation lysis buffer containing 1% Triton X-100, 0.5% 
sodium deoxycholate, and 0.5% SDS and re-centrifuged at 100,000 x g for 20 
minutes at 4°C. This supernatant represents the membrano-cytoskeletal (lysis) 
fraction. Both the TBS and lysis buffers included protease and phosphatase 
inhibitors as previously described to prevent proteolysis and dephosphorylation 
of the tissue samples (Calon et al., 2004). For Western immunoblotting (WB), 
protein concentrations were determined using the Bio-Rad DC protein assay.  
Each sample contained 30g of protein and was boiled in Laemmli sample 
buffer for 3 minutes prior to being loaded into a 34 lane 7-20% Tris-glycine 
gradient gel. Gels were electrophoresed, then transferred to Immobilon-P PVDF 
membranes (Millipore, Bedford, MA) as previously described (Ma et al., 2006).  
Blots were developed in the linear range with chemiluminescent detection and 
relative optical density on film scanned with a Biorad densitometer (Calon et al., 
2004).   
NP1 ELISA. Plasma NP1 levels were measured using a commerical ELISA kit 
(Aviva System Biology; human, OKDD0433, San Diego, CA) per the 
manufacturer’s recommended protocol. Briefly, 100 l of serially titrated NP1 
standards and two times diluted plasma samples were added into wells of the 
Anti-NP1 pre-coated micro-well plate. Two replicates of each standard and 
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sample were used for the assay.  The plate was incubated at RT for 2 hr on a 
shaker plate. After washing with TBS, 100 l of biotinylated mouse anti-NP1 
detector antibody was added and incubated at RT for 1 hr. Then, 100 l of 
Avidin-HRP conjugate was added and incubated for 1 hr. After washing with 
TBS, 90 l of TMB substrate was added and incubated for 20 minutes, then 50 l 
of stop solution was added and the absorbance was measured at 450 nm. 
Plasma NP1 concentrations were then calculated from the standard curve. The 
% of CV cutoff was above 10%, we excluded samples with CV’s > 10% for data 
analysis.  
Human Plasma. Human plasma samples from APOE-genotyped 
cognitively normal elderly (NC, n = 31) and patients with mild cognitive 
impairment (MCI, n = 33) were obtained from the ImaGene Study (Ramirez et al., 
2016) conducted through the UCLA Easton Alzheimer Center. Over three years 
of longitudinal follow-up during this study, a subset of MCI subjects subsequently 
progressed to probable mild AD dementia (EAD; n = 11); the remainder 
continued to meet diagnostic criteria for MCI (MCI; n = 22).   
Statistical analysis. Analyses of biochemical and immunohistochemical 
data were performed using StatView 5.0 software. Group differences were 
compared using t-tests or analysis of variance (ANOVA). Post hoc comparisons 
were performed using Fisher LSD where appropriate. 
 
Results 
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Plasma levels of NP1 and its fragments were increased in E4FAD mice 
and responded to DHA treatment. WB data for plasma levels of NP1 and its 
associated fragments are shown in Figure 1. The two primary NP1 species 
identified by WB in EFAD mouse plasma were a full-length band at ~50 kDa and 
a shorter fragment at ~38 kDa (Figure 1A, center lane). While both of these 
bands were also seen in the lane loaded with recombinant NP1 protein (Figure 
1A, left lane), they were not seen in plasma from NP1 knockout mice (Figure 1A, 
right lane; gift from M. A. Hossein, Kennedy Kreiger Institute, Johns Hopkins 
University), suggesting that the ~50 kDa and ~38 kDa bands visualized on WB 
are NP1 specific. 
A representative WB for NP1 in plasma samples from 7~8-month-old 
E4FAD and E3FAD mice is shown in Figure 1B. Quantitative analyses indicated 
that E4FAD mice had significantly higher levels of both full-length NP1 (Figure 
1B; p<0.001) and the ~38 kDa NP1 fragment (Figure 1C; p<0.01) than E3FAD 
mice. Plasma levels of the ~50 kDa and ~38 kDa NP1 species were closely 
correlated (Figure 1D; r2=0.795, p<0.001). 
Prior work from our group has also shown that dietary DHA 
supplementation ameliorates excitatory synaptic pathology in Tg2576 mice 
(Calon et al., 2004, Calon et al., 2005). Since plasma NP1 species represent 
potential peripheral biomarkers of synaptic dysfunction, we examined the effects 
of DHA supplementation on these markers in E3FAD and E4FAD mice. E4FAD 
mice maintained on the DHA-supplemented diet from 3 to 7~8 months of age had 
significantly lower levels of full-length NP1 (Figure 1B; p<0.01) and the ~38 kDa 
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NP1 fragment (Figure 1C; p<0.05) relative to E4FAD mice maintained on the 
DHA-depleted diet. Plasma levels of each of these markers in DHA-
supplemented E4FAD mice approximated those seen in E3FAD mice.  
Hippocampal NP1 levels were increased in E4FAD mice and responded to 
DHA treatment. We subsequently sought to determine whether these observed 
changes in the levels plasma NP1 species reflected changes in hippocampal 
NP1 expression. WB data for NP1 levels in E3FAD and E4FAD hippocampus are 
shown in Figure 2. Full length NP1 levels were numerically higher in E4FAD 
versus E3FAD mice, but this difference fell short of statistical significance (Figure 
2A; p = 0.098). Significantly higher levels of the ~38 kDa NP1 fragment were 
seen in E4FAD versus E3FAD mice (Figure 2B; p<0.01). Dietary DHA 
supplementation treatment in E4FAD mice significantly reduced both the full-
length (Figure 2A; p< 0.05) and ~38 kDa  (Figure 2B; p<0.01) NP1 species to 
levels comparable to those seen in the E3FAD mice. Furthermore, across all 
E4FAD animals, hippocampal levels of full-length NP1 were significantly 
correlated with plasma levels of both the full-length (Figure 2C; r2=0.538, 
p=0.002) and ~38 kDa (Figure 2D; r2=0.269, p=0.048) NP1 species. 
 
Elevations of plasma and brain NP1 levels in E4FAD mice were FAD  
transgene dependent. We subsequent sought to determine the relative effects of 
APOE4 expression and Aβ overproduction on plasma and brain NP1 levels. 
Figure 3 illustrates relative plasma NP1 levels in E4FAD and E4FAD- mice. 
While differences in plasma levels of full-length NP1 between E4FAD and 
E4FAD- mice failed to reach statistical significance (Figure 3A; p > 0.05), the 
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E4FAD mice had significantly higher plasma levels of the 38 kDa NP1 fragment 
(Figure 3B; p=0.05). Immunohistochemical analyses were used to compare brain 
NP1 expression between E4FAD and E4FAD- mice (Figure 4). Confocal imaging 
in 7-month-old mice demonstrated increased cortical NP1 expression in E4FAD 
mice relative to E4FAD- mice (Figure 4A). Likewise, hippocampal NP1 levels 
were significantly higher in E4FAD mice (Figures 4B and 4C; p<0.001). Taken 
together these data suggest that both APOE genotype and Aβ overproduction 
may contribute to increased central and peripheral NP1 levels.  
 
 Aβ42 oligomer infusions increased brain NP1 expression in wild type 
mice. Since the mutant APP and PS1 transgenes that are overexpressed in 
EFAD mice may have effects beyond Aβ overproduction, we sought to confirm 
the effects of Aβ on brain NP1 expression using icv infusions in wild type (WT) 
mice. Aβ was infused as a solution of Aβ42 oligomers (oAβ), which represent an 
important toxic Aβ species that contributes to synaptic and cognitive deficits 
(Gong and Iqbal, 2008, Danysz and Parsons, 2012, Ma et al., 2013). Figure 5 
shows representative hippocampal Aβ and NP1 staining after 2 weeks of oAβ or 
vehicle infusion into the right ventricles of 4-month-old WT mice. Infusions of oAβ 
increased deposition of both Aβ (Figure 5A) and NP1 (Figure 5B). These results 
confirm prior work in neuronal cell culture indicating that Aβ can induce NP1 
expression (Abad et al., 2006). 
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Plasma NP1 levels were elevated in patients with mild cognitive impairment 
(MCI) and in cases of early-stage AD that had progressed from MCI (EAD). 
Previous work has indicated that brain NP1 levels are increased in both 
APP/PS1 mice and human patients with sporadic late-onset AD (Abad et al., 
2006). Therefore, we examined whether the plasma NP1 elevations seen in 
E4FAD mice would be detectable in human plasma samples. Because NP1 is 
enriched in excitatory synapses that are lost with AD progression (Mota et al., 
2014) and transgenic rodent models of AD are thought to represent very early 
stages of disease progression (Ashe, 2005), we focused on plasma samples 
from MCI, including those that subsequently progressed to mild AD dementia, 
and age-matched cognitively normal elderly (NC). Sandwich ELISA analysis of 
plasma NP1 demonstrated significantly higher levels in patients with MCI (p < 
0.05, Figure 6A) and even higher levels in early-stage AD (p < 0.001, Figure 6A) 
relative to age-matched cognitively normal elderly. In our small early AD 
subgroup, NP1 also showed a trend for an increase in APOE4 carriers compared 
to APOE4 non-carriers (p =0.078, Fig 6B). While these results require 
confirmation with a much larger sample, they support the hypothesis that 
increased plasma NP1 levels may reflect early excitatory synapse loss in MCI 
and early AD, and are modulated by the APOE4 genotype with progressive 
disease.  
 
 Plasma NP1 was enriched in plasma exosome fractions from E4FAD 
mice. It remains uncertain how synapse-specific proteins such as NP1 are 
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transported from the brain to the plasma. One potential mechanism is via 
exosomes. Prior work has shown that NP1 is present in human CSF exosome-
enriched extracellular vesicles (EVs) (Chiasserini et al., 2014). We investigated 
whether NP1 is present in plasma EVs. EVs were isolated from pooled plasma of 
E4FAD mice and probed by WB for NP1 (Figure 7). We compared two 
independent pooled plasma samples from E4FAD mice (n=4/group). Figure 7 
demonstrates the relative enrichment of NP1 in plasma EV fractions (which 
contain the exosome marker ALIX) relative to whole plasma and post-
ultracentrifugation supernatant fractions. These results suggest that NP1 may be 
exported from brain via exosomes or other extracellular vesicles, though we 
cannot rule out the possibility that NP1 may merely represent a contaminant 
within exosome-enriched fractions. 
 
Discussion  
The purpose of this study was to determine whether brain and/or plasma 
levels of NP1 reflect Aβ- and APOE4-associated synaptic deficits in animal 
models of AD, as well as in MCI and probable AD dementia cases.  In the 
experiments described above, we demonstrate that the expression of both full 
length NP1 (~50 kDa) and a 38 kDa NP1 fragment were increased in a correlated 
fashion between hippocampal and plasma samples from E4FAD mice compared 
to E3FAD mice. Brain and plasma NP1 levels appear to reflect treatable synaptic 
dysfunction, as dietary DHA supplementation resulted in increased expression of 
excitatory synaptic markers and decreased expression of NP1 in E4FAD mice. 
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As suggested by prior work (Abad et al., 2006), increased plasma and brain NP1 
levels appear to be mediated in part through increased Aβ expression. 
Furthermore, plasma NP1 levels were also increased in patients with MCI 
(particularly those who subsequently progressed to AD dementia) relative to 
cognitively normal elderly. Within the small progressive MCI subgroup, NP1 
levels were marginally higher in APOE4 carriers relative to non-carriers. Taken 
together, these data indicate that plasma NP1 species may serve as potential Aβ 
and APOE4-dependent biomarkers of early synaptic dysfunction in AD. Although 
the precise mechanism by which these NP1 species reach the plasma remains 
uncertain, they may be trafficked from the brain via extracellular vesicles, 
possibly exosomes, after endocytosis and processing. 
         NP1 is one of a family of neuronal pentraxins (NPs) that appear to play 
important roles in both synaptic remodeling and neuronal apoptosis. NP1 is 
predominantly expressed in neurons at high concentrations in the hippocampus, 
cerebellum, and cerebral cortex (Schlimgen et al., 1995). NP1 is enriched at 
excitatory synapses and functions closely associated with NP2 (Narp) and 
AMPARs. NP1 interacts with the N-terminal domain of the AMPA receptor GluA4 
subunit to mediate GluA4 synaptic recruitment (Sia et al., 2007). NP1 and NP2 
form heterocomplexes that are required in vivo for the normal development of 
AMPAR-mediated transmission and function in developmental and activity-
dependent synaptic plasticity (Xu et al., 2003, Sia et al., 2007, Koch and Ullian, 
2010).  NPR and NP1 interact directly with GluA1 and increase GluA1 currents 
and puncta intensity; this adds support to a model in which NPR recruits and 
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stabilizes NP1 and NP2 on the presynaptic plasma membrane where NPR acts 
in excitatory synapse assembly by binding to the N-terminal domain of AMPARs 
(Lee et al., 2017).  Moreover, NP1 regulates the surface expression of the Kv7.2 
subunit of the Kv7 family of potassium channels that control neuronal excitability 
(Figueiro-Silva et al., 2015). In mature neurons, NP1 negatively regulates 
excitatory density and synaptic plasticity (Figueiro-Silva et al., 2015), a process 
known to be Aβ oligomer sensitive (Guntupalli et al., 2016). Elevations in NP1 
can be seen in a number of pro-apoptotic conditions (DeGregorio-Rocasolano et 
al., 2001, Hossain et al., 2004, Enguita et al., 2005) and contribute to 
mitochondrial damage and neuronal death (Clayton et al., 2012, Al Rahim et al., 
2013). 
Prior work suggests that NP1 facilitates neurodegeneration in AD, as its 
expression is increased in dystrophic neurites around plaques in postmortem AD 
brain and in transgenic AD mice (Abad et al., 2006, Cummings et al., 2017, 
Neuner et al., 2017). Cell culture studies suggest that Aβ-associated neuronal 
apoptosis is mediated through GSK-3β induced increases in NP1 expression 
(Abad et al., 2006, Russell et al., 2011). Our findings that NP1 levels were 
significantly higher in the brain of E4FAD mice relative to E4FAD- mice, and in 
WT mice infused with Aβ42 relative to vehicle, confirm the relationship between 
Aβ and NP1 and raise the possibility that plasma NP1 levels reflect the 
downstream effects of cerebral Aβ neurotoxicity.  In human study, we found 
plasma NP1 levels were significantly elevated in MCI and early AD, suggesting 
that the alteration of CSF and/or plasma NP1 might be independent on NP2 and 
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also disease-stage dependent reflecting synaptic pathology. Less NP1 elevation 
observed in AD or later stages of AD might be caused by extensive loss of its 
synaptic sources (Llano et al., 2017, Brinkmalm et al., 2018).  
           In our study with a small subgroup, we found that plasma NP1 had a trend 
increase in the subjects with APOE4 carriers who had recently progressed from 
MCI to AD dementia. Similarly, our animal study shows higher brain and plasma 
NP1 levels in E4FAD versus E3FAD mice. These data suggesting that APOE4-
associated synaptic dysfunction (Klein et al., 2010) may closely link to NP1 
dysfunction. The APOE ε4 allele is the major genetic risk factor for the late onset 
AD (Corder et al., 1993, Kim et al., 2009). While some of this increased risk 
appears to be mediated through Aβ-associated mechanisms (Christensen et al., 
2010, Hashimoto et al., 2012, Koffie et al., 2012), other APOE4-associated 
effects on dendritic spine density and morphology (Dumanis et al., 2009, Klein et 
al., 2010), glutamate receptor function and reelin-induced enhancement of long-
term potentiation (Chen et al., 2010) appear to be independent of (and 
synergistic with) Aβ pathophysiology. Prior work with EFAD- mice has shown 
impaired synaptic plasticity (Trommer et al., 2004) and decreased expression of 
synaptic markers such as drebrin (Nwabuisi-Heath et al., 2014) in APOE4-TR 
versus APOE3-TR animals.  
Prior work from our group and others has demonstrated that DHA 
supplementation protects against Aβ-associated depletion of synaptic markers 
such as drebrin, NR2B and PSD-95 in Tg2576 mice (Calon et al., 2004, Calon et 
al., 2005) and drebrin in APPsw/PS1ΔE9 mice (Perez et al., 2010). DHA 
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supplementation in the current study in E4FAD mice showed reduced brain and 
plasma levels of NP1 species. While DHA treatment has not been shown to 
improve outcomes in mild-to-moderate AD dementia patients who carry an 
APOE4 allele (Quinn et al., 2010), it does appear to have beneficial effects on 
MCI (Sinn et al., 2012, Lee et al., 2013, Bo et al., 2017). Furthermore, recent 
data indicate that increased consumption of seafood (which has high DHA levels) 
is associated with decreased AD neuropathology in APOE4 carriers (Morris et 
al., 2016).  
 Although it remains uncertain how NP1 may be transported from brain to 
plasma, we observed that NP1 (both full length and a 38 kDa fragment) were 
found in plasma exosome enriched fractions in animals. This is consistent with 
the presence of NP1 peptides in extracellular vesicle (EV)/exosome fractions 
isolated from pooled samples of human CSF (Chiasserini et al., 2014). 
Exosomes are small vesicles derived from the multivesicular bodies (MVBs) of 
the endocytic pathways that can cross the blood-brain barrier (Zhuang et al., 
2011, Kalani et al., 2014, Andras and Toborek, 2016). Since NP1 interacts with 
AMPA-type glutamate receptors that participate in excitatory synaptic 
transmission involved in learning and memory, and neural exosomes contain 
GluR2/3 subunits of glutamate receptors (Faure et al., 2006), the detection NP1 
species in exosome-enriched plasma fractions may reflect alterations in AMPA 
receptor function or expression during early stages of AD pathophysiology. The 
independently regulated NP2 is also found in plasma neural exosomes where it 
was recently reported to be decreased in AD along with GluA4 (Goetzl et al., 
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2017).    
However, there are a number of limitations to using plasma NP1 as a 
specific biomarker for AD. First, hypoxic-ischemic injury can induce NP1 
expression (Hossain et al., 2004). Second, although NP1 is thought to be 
exclusively expressed in brain and was not detected in heart, skeletal muscle, 
placenta, lung, liver, pancreas, or kidney samples from humans, rats, and mice 
(Hsu and Perin, 1995, Omeis et al., 1996), it remains possible that a portion of 
the NP1 found in plasma might be derived from heretofore unexamined 
peripheral sources. Third, only a small subgroup of human MCI patients 
progressed to mild AD dementia represents. While there was a trend towards 
higher plasma NP1 levels amongst APOE4 carriers versus non-carriers in this 
subgroup, this finding needs to be validated with a much larger sample size.  
 
Conclusion  
We found that NP1 species were significantly increased in both plasma and brain 
samples of E4FAD mice in a correlated fashion. NP1 species were also 
increased in human plasma samples from patients diagnosed with MCI 
(particularly those who subsequently progressed to AD dementia) relative to 
cognitively normal elderly. These elevations of NP1 at earlier stages of AD 
pathophysiology may parallel the process of synapse loss. In E4FAD mice, these 
increases in NP1 were ameliorated by dietary DHA supplementation. Since NP1 
may be involved in progressive excitatory synapse loss associated with Aβ and 
APOE4, our findings suggest that NP1 may represent a potential plasma 
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biomarker for excitatory synaptic dysfunction in MCI and early AD, which could 
be used to monitor disease progression and/or response to therapeutic 
interventions. 
Figure legends 
 
Figure 1. Plasma NP1 species are increased in E4FAD mice and reduced by 
dietary DHA supplementation.  A. Both 50 kDa NP1 band and 38 kDa NP1 
reactive fragments were absent in NP1 KO mice plasma, mouse IgG control and 
secondary (2nd) antibody alone lanes, but present in the NP1 recombinant 
protein loading lane, suggesting that these are NP1 specific reactive bands. 
Western blot analysis showed that plasma 50 kDa NP1 (p < 0.001, B), a 38 kDa 
NP1 reactive fragment (p < 0.01, B, C) were significantly increased in 7-8 month-
old E4FAD mice compared to age-matched E3FAD mice. After EFAD mice were 
treated by 0.6% DHA from 3 to 7~8 months, DHA significantly reduced 50 kDa (p 
< 0.01, B) and 38 kDa NP1 species (p < 0.05, C) in E4FAD mice, but not in 
E3FAD mice. D. The plasma 50 kDa NP1 and 38 kDa NP1 fragments were 
significantly correlated (R⌃ 2 = .795, p < 0.0001).  Error bars represent + s.e.m. 
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, one-way ANOVA test. In this 
figure,  E3 indicates E3FAD mice and E4 indicates E4FAD mice. +D indicates 
DHA treated groups. 
 
Figure 2. Brain NP1 species, are increased in E4FAD mice and reduced by 
dietary DHA supplementation; brain and plasma NP1 levels are correlated 
in E4FAD mice. 
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A. Western blot analysis showed a trend to an increase in 50 kDa NP1 band (p = 
0.098, NS) in E4FAD mice compared to E3FAD mice, while DHA treatment 
significantly reduced it in DHA-treated E4FAD mice compared to untreated 
E4FAD mice (p < 0.05). B. 38 kDa NP1 fragments were increased in E4FAD 
mice compared to E3FAD mice, (p < 0.01), while DHA treatment significantly 
reduced 38kDa NP1 fragment in DHA-treated E4FAD mice compared to 
untreated E4FAD mice (p<0.01). C. Brain 50 kDa NP1 significantly correlated 
with plasma 50 kDa NP1 in E4FAD mice (R2 = 0.538, p = 0.002). D.  Brain 50 
kDa NP1 was also significantly correlated with plasma levels of the 38 kDa NP1 
fragment in E4FAD mice (R2 = 0.269, p = 0.048). In this figure, E3 indicates 
E3FAD mice and E4 indicates E4FAD mice. +D indicates DHA treated groups. 
 
Figure 3. The elevation of Plasma NP1 in E4FAD mice is FAD transgene 
dependent. A. Western blot analysis showed no statistical significance 
differences in plasma 50 kDa NP1 band in E4FAD mice compared to E4FAD- 
mice (p > 0.05, with both on 5015 diet). B. Western blot analysis showed 
increases in plasma 38 kDa NP1 fragment in E4FAD mice compared to E4FAD- 
mice (p = 0.05). 
 
Figure 4. The elevation of brain NP1 in E4FAD mice is FAD transgene 
dependent. A. Immunohistochemistry by confocal imaging revealed brain cortex 
NP1 was increased in 7-month-old E4FAD mice compared to age-matched 
E4FAD- mice. B, C Quantification of brain hippocampal NP1 from DAB staining 
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indicated that NP1 was significantly increased in E4FAD mice compared to 
E4FAD- mice (p < 0.0001) (with both on 5015 diet).  
 
Figure 5. Aβ42 oligomers infusion increases brain NP1. After infusing 50 µg 
of Aβ42 oligomers (OAβ) into right ventricle of 4-month-old wile type (WT) mice 
over 2 weeks, brain adjacent serial sections were used for Aβ and NP1 staining. 
A. Aβ Deposition (red) was observed by immunostaining with anti-Aβ antibody, 
DAE, in the dentate gyrus of the hippocampus in OAβ-infused WT mice but not in 
the vehicle (Veh)-infused mice.  B. NP1 (green) was increased in the dentate 
gyrus of the hippocampus in OAβ-infused WT mice but not in the Veh-infused 
mice. Quantification of immunostained NP1 cells confirmed a significant 
difference between the two groups (p < 0.001). 
 
Figure 6. Plasma NP1 levels are increased in MCI and early AD dementia. A. 
ELISA analysis showed that plasma NP1 was increased in patients with MCI (p < 
0.05) and early AD (EAD, p < 0.01) relative to normal cognitive elderly (NC).  B. 
In the EAD group, NP1 showed a trend increases in APOE4 carriers (E4+) 
relative to non-APOE4 carriers (E4-).   
 
Figure 7. Plasma NP1 and NP1 fragments are enriched in exosomes 
containing fractions isolated from pooled plasma of E4FAD mice.  
Plasma extracellular vesicles were isolated from pooled plasma of human and 
E4FAD mice via ultracentrifugation.  Western blot analysis revealed that NP1 
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species were enriched in E4FAD plasma exosome enriched fractions. Western 
blot results demonstrated levels of NP1 and NP1 fragments in plasma before 
ultracentrifugation (pla, whole plasma) were reduced or depleted in the 
supernatant (sup) after pelleting of exosomes (Exo) using ultracentrifugation in 
two independent pooled plasma groups of E4FAD mice (n=4/per group).  NP1 
and its fragments were enriched in the pellet extracellular vesicle fractions, which 
contain the exosome marker ALIX.  
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